Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6381
Peer-review started: September 25, 2014
First decision: October 29, 2014
Revised: November 26, 2014
Accepted: January 8, 2015
Article in press: January 8, 2015
Published online: May 28, 2015
Achalasia is a rare esophagus motility disorder. Medical, endoscopic and surgical treatments are available, but all endorse high relapse rates. No data has been published to date reporting a therapeutic effect of cannabis use neither in achalasia nor on its influence on manometric measurements. We report the case of a patient diagnosed with achalasia. He could benefit from a large panel of therapeutic interventions, but none of them was effective over the time. He first used cannabis at age 20 and identified benefits regarding achalasia symptoms. He maintained regular moderate cannabis use for 9 years, with minimal digestive inconvenience. A manometry performed without cannabis premedication was realized at age 26 and still found a cardiospasm. Cannabis use could explain the gap between functional symptoms assessment and manometry measurement. Further investigations are warranted to explore a therapeutic effect of cannabis in achalasia and possible influence on outcome measurements.
Core tip: Achalasia is a rare esophagus motility disorder. Medical, endoscopic and surgical treatments are available, but all endorse high relapse rates. We report the case of a patient diagnosed with achalasia who identified benefits from cannabis use on achalasia symptoms. Cannabis non-use before manometry could explain the gap between functional symptoms assessment and manometry measurement. Further investigations are warranted to explore a therapeutic effect of cannabis in achalasia and possible influence on outcome measurements. Particular attention should be given to cannabis addiction risk to vulnerable patients.
- Citation: Luquiens A, Lourenco N, Benyamina A, Aubin HJ. Self-medication of achalasia with cannabis, complicated by a cannabis use disorder. World J Gastroenterol 2015; 21(20): 6381-6383
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6381.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6381
Achalasia is a rare esophageal motility disorder characterized by the absence of peristalsis and impaired relaxation of the lower esophageal sphincter. The main symptoms are dysphagia, regurgitation, heartburn, chest pain and weight loss. The effectiveness of medical treatment is inconsistent, and no trial could support the effectiveness of nitrates or calcium-channel blockers. Endoscopic treatment, namely pneumatic dilation and botulinum toxin injection, requires frequent interventions. Surgical options, namely laparoscopic cardiomyotomy and esophagectomy, are proposed for end-stage achalasia and have high relapse rates.
To our knowledge, no data have been reported on the therapeutic effect of cannabis in achalasia, nor on the influence of cannabis on manometric measurements.
Medical cannabis extract (Nabiximols) is approved in several countries for the treatment of refractory spasticity in multiple sclerosis. Commercialized nabiximols is standardized to contain dronabinol and Cannabidiol (CBD) in a ratio of 1:1 and is sprayed under the tongue using a dose pump. Cannabidiol is the most important non-psychotropic cannabinoid found in the cannabis plant. It is not a cannabinoid (CB) receptor agonist. Dronabinol is the international non-proprietary name for (-)-trans-delta-9-tetrahydrocannabinol (THC). THC is used to refer to the naturally occurring (-)-trans-isomer of delta-9-tetrahydrocannabinol from the cannabis plant (Cannabis sativa L.). THC is a CB receptor agonist. THC is responsible for most of the pharmacological actions of cannabis, including the psychoactive effects. Medical cannabis showed positive results for spasticity in patients with multiple sclerosis[5,6] or paraplegia and in the treatment of anorexia, nausea, and neuropathic pain.
A 31-year-old patient came to our addiction clinic seeking care for a cannabis use disorder. He was diagnosed with achalasia at the age of 17, with high disability linked to severe symptoms: Regurgitation of undigested food, dysphagia for solid food, heartburn. He initially benefited from nitrate medication but suffered from unacceptable headaches, that led to treatment discontinuation. At age 18, the symptoms were increasingly severe, resulting in a weight loss of 27% of body weight associated with food disgust. He then benefited from a laparoscopic cardiomyotomy, which improved symptoms for one year and a half before relapse. At age 20, a manometry confirmed relapse with impaired relaxation of the lower esophageal sphincter, and major diffuse esophageal dyskinesia. He first used cannabis and identified benefits regarding achalasia symptoms, specifically with food intake facilitation and weight intake. He maintained regular cannabis use of one joint a day for 9 years. During this time period, he did not lose weight, suffered from minimal inconvenience. A manometry realized at age 26 still found a cardiospasm that did not allow the passage of the catheter. This manometry was performed without cannabis premedication, whether the food intakes were pre-medicated by cannabis use at this time period. This could explain the gap between functional symptoms assessment and manometry measurement. He stopped cannabis use at age 29 for a short time period, but suffered from immediate relapse of previous digestive symptoms. At age 29 a first pneumatic dilatation at 30 mm did not allow to facilitate food intakes. He decided to handle his digestive symptoms by cannabis consumption, leading to their improvement, enduring no more weight loss and only sporadic dysphagia. At age 30, negative life events were followed by increased cannabis use that escalated to a severe cannabis use disorder.
Our research was conducted in accordance with the Helsinki Declaration, and the patient gave written informed consent for publication.
This spontaneous report of a therapeutic effect of cannabis on achalasia symptoms provides a promising and innovative therapeutic approach. The mechanism of action could involve smooth muscle relaxation of the lower esophageal sphincter, as the endogenous ligand of CB1, anandamide, is an effective antispasticity agent[7,8]. CB1 receptors are primarily presynaptic; their activation inhibits calcium influx and glutamate release and reduces neuronal excitability by activating somatic and dendritic potassium channels. A relaxing effect on other smooth muscles has been reported. CBD is also known for its anti-emetics properties. Therapeutic effect of cannabis in achalasia could then be due to both CBD and THC actions. Further investigations are warranted to explore a therapeutic symptomatic effect of cannabis in achalasia and the physiopathology of this potential effect. Use of cannabis should be taken into account to analyze outcome measurements, in particular manometric findings, and their correlates to functional symptoms.
Cannabis abuse potential is well documented. Although smoked cannabis contains over 400 other chemicals (about 60 are cannabinoids), its reinforcing effects are known to be due to Delta-9-THC. A ratio 1:1 of CBD and THC seems to be protective from addiction-onset risk. Medical cannabis seems to have a much less addictive potential than those of smoked cannabis. However, particular attention should be given to cannabis addiction risk to vulnerable patients.
A 31-years-old patient suffers from achalasia since 17 years old. Medical, endoscopic and surgical treatments failed. Symptoms were improved by cannabis consumption, which was complicated by a cannabis use disorder.
Main clinical symptoms of achalasia were dysphagia, heartburn and weight loss.
Endoscopic exploration and two manometries confirmed achalasia.
No laboratory blood test found any consequence of weight loss (no malnutrition or deficiency).
Manometry was performed two times after surgical cardiomyotomy, and confirmed esophageal dyskinesia.
Pathological examination was not performed.
First line medical treatment (nitrites) and second line surgical treatment and pneumatic dilatation failed in preventing long time symptoms return; cannabis consumption was described by the patient as facilitating food and weight intake.
This is the first case report of the effects of cannabis on achalasia symptoms. It provides a promising therapeutic approach in a field with limited medical, endoscopic and surgical therapeutics, which endorse high relapse rates.
The human endocannabinoid system comprises two major cannabinoid receptors (CB1 and CB2, expressed primarily in central nervous system tissues and immune cells, respectively) and their endogenous ligands, known as endocannabinoids.
This is the first description of effects of cannabis on esophagus motility disorder probably involving smooth muscle relaxation of the lower esophageal sphincter, nevertheless other effects of cannabis on smooth muscles were previously reported.
The present manuscript presents a case study speaking to the efficacy of cannabis for the treatment of achalasia in a 31-year-old patient. Findings highlight the potential therapeutic effect of cannabis for this rare esophageal disorder.
P- Reviewer: Bonn-Miller MO S- Editor: Ma YJ L- Editor: A E- Editor: Zhang DN
|1.||Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet. 2014;383:83-93. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 390] [Cited by in F6Publishing: 390] [Article Influence: 43.3] [Reference Citation Analysis (0)]|
|2.||Wen ZH, Gardener E, Wang YP. Nitrates for achalasia. Cochrane Database Syst Rev. 2004;CD002299. [PubMed] [Cited in This Article: ]|
|3.||Blatnik JA, Ponsky JL. Advances in the treatment of achalasia. Curr Treat Options Gastroenterol. 2014;12:49-58. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis (0)]|
|4.||Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109:495-501. [PubMed] [Cited in This Article: ]|
|5.||Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult Scler Relat Disord. 2012;1:64-75. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis (0)]|
|6.||Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014;74:563-578. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis (0)]|
|7.||Su JY, Vo AC. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol. 2007;559:189-195. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis (0)]|
|8.||Leung L. Cannabis and its derivatives: review of medical use. J Am Board Fam Med. 2011;24:452-462. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 5.7] [Reference Citation Analysis (0)]|
|9.||Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184:1143-1150. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 121] [Cited by in F6Publishing: 131] [Article Influence: 11.9] [Reference Citation Analysis (0)]|
|10.||Dudásová A, Keir SD, Parsons ME, Molleman A, Page CP. The effects of cannabidiol on the antigen-induced contraction of airways smooth muscle in the guinea-pig. Pulm Pharmacol Ther. 2013;26:373-379. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis (0)]|
|11.||Cho YK, Lipowska AM, Nicodème F, Teitelbaum EN, Hungness ES, Johnston ER, Gawron A, Kahrilas PJ, Pandolfino JE. Assessing bolus retention in achalasia using high-resolution manometry with impedance: a comparator study with timed barium esophagram. Am J Gastroenterol. 2014;109:829-835. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis (0)]|
|12.||Office On Drugs And Crime. World Drug Report. United Nations Pub. 2006;103-105 Available from: http://www.unodc.org/pdf/WDR_2006/wdr2006_volume1.pdf?bcsi_scan_628cd39dca2568d2=W/uF5TgpZiKH1n4umehwPHkYXEQCAAAAQ/5BEQ==&bcsi_scan_filenam. [Cited in This Article: ]|
|13.||Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl). 2005;181:237-243. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis (0)]|
|14.||Russo EB. The solution to the medicinal cannabis problem. Ethical issues in chronic pain management. New York: Informa Healthcare 2006; 165-194. [Cited in This Article: ]|
|15.||Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011;26:224-236. [PubMed] [Cited in This Article: ]|